Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis? - PubMed (original) (raw)
. 1997 Oct;289(11):623-30.
doi: 10.1007/s004030050251.
Affiliations
- PMID: 9444385
- DOI: 10.1007/s004030050251
Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis?
K Asadullah et al. Arch Dermatol Res. 1997 Oct.
Abstract
Although the effectiveness of systemic antipsoriatic treatment with fumaric acid esters has been proven, their mode of action is still not understood. Recent results indicate their potency in inducing cytokine production in stimulated T cells. Since monocytes and their cytokines are also considered to be of pathogenic importance in psoriasis, we investigated the effect of monomethylfumarate (MMF) on proinflammatory (TNF-alpha, IL-12) and antiinflammatory (IL-10, IL-1RA) cytokine production by peripheral blood mononuclear cells (PBMC) and separated monocytes. In 24-h PBMC cultures from both psoriatic patients (n = 6-13) and healthy volunteers (n = 7-9), MMF at 100 microM induced secretion of TNF-alpha, IL-10, and IL-1RA. Kinetics of IL-10 protein and mRNA expression indicated de novo production. Moreover, MMF significantly augmented endotoxin-induced synthesis of TNF-alpha, IL-10 and IL-1RA. In contrast, no influence on IL-12 secretion was found. Similar effects of MMF in purified monocytes indicated these cells to be responsible for aberrant cytokine formation. Furthermore, enhanced expression of costimulatory molecules after MMF stimulation confirmed monocyte activation. Multiple restimulation with fumaric acid esters in vitro, however, and immunomonitoring in a patient during Fumaderm initial therapy suggested that initial monocyte activation is followed by subsequent deactivation associated with an antiinflammatory response. Our results may explain the well-known effects of therapy with fumaric acid esters. Thus, initial treatment is often accompanied by adverse effects which may be caused by MMF-induced TNF-alpha formation. The change in the IL-10/IL-12 balance as a result of elective induction of IL-10, however, may have antipsoriatic activity by diminishing type-1/proinflammatory cytokine over-expression and the antigen-presenting capacity of monocytes/macrophages, and by upregulation of IL-1RA.
Similar articles
- Effects of monomethylfumarate on dendritic cell differentiation.
Litjens NH, Rademaker M, Ravensbergen B, Thio HB, van Dissel JT, Nibbering PH. Litjens NH, et al. Br J Dermatol. 2006 Feb;154(2):211-7. doi: 10.1111/j.1365-2133.2005.07002.x. Br J Dermatol. 2006. PMID: 16433787 - Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate.
de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. de Jong R, et al. Eur J Immunol. 1996 Sep;26(9):2067-74. doi: 10.1002/eji.1830260916. Eur J Immunol. 1996. PMID: 8814248 - The antipsoriatic agent monomethylfumarate has antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes.
Helwa I, Patel R, Karempelis P, Kaddour-Djebbar I, Choudhary V, Bollag WB. Helwa I, et al. J Pharmacol Exp Ther. 2015 Jan;352(1):90-7. doi: 10.1124/jpet.114.218818. Epub 2014 Oct 20. J Pharmacol Exp Ther. 2015. PMID: 25332455 Free PMC article. - Fumaric acid esters.
Rostami Yazdi M, Mrowietz U. Rostami Yazdi M, et al. Clin Dermatol. 2008 Sep-Oct;26(5):522-6. doi: 10.1016/j.clindermatol.2008.07.001. Clin Dermatol. 2008. PMID: 18755371 Review. - The Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects.
Mrowietz U, Morrison PJ, Suhrkamp I, Kumanova M, Clement B. Mrowietz U, et al. Trends Pharmacol Sci. 2018 Jan;39(1):1-12. doi: 10.1016/j.tips.2017.11.002. Epub 2017 Nov 25. Trends Pharmacol Sci. 2018. PMID: 29183628 Review.
Cited by
- Macrophage fumarate hydratase restrains mtRNA-mediated interferon production.
Hooftman A, Peace CG, Ryan DG, Day EA, Yang M, McGettrick AF, Yin M, Montano EN, Huo L, Toller-Kawahisa JE, Zecchini V, Ryan TAJ, Bolado-Carrancio A, Casey AM, Prag HA, Costa ASH, De Los Santos G, Ishimori M, Wallace DJ, Venuturupalli S, Nikitopoulou E, Frizzell N, Johansson C, Von Kriegsheim A, Murphy MP, Jefferies C, Frezza C, O'Neill LAJ. Hooftman A, et al. Nature. 2023 Mar;615(7952):490-498. doi: 10.1038/s41586-023-05720-6. Epub 2023 Mar 8. Nature. 2023. PMID: 36890227 Free PMC article. - The Nrf2 Pathway in Ischemic Stroke: A Review.
Farina M, Vieira LE, Buttari B, Profumo E, Saso L. Farina M, et al. Molecules. 2021 Aug 18;26(16):5001. doi: 10.3390/molecules26165001. Molecules. 2021. PMID: 34443584 Free PMC article. Review. - Neuroprotection and immunomodulation by dimethyl fumarate and a heterologous fibrin biopolymer after ventral root avulsion and reimplantation.
Kempe PRG, Chiarotto GB, Barraviera B, Ferreira RS Jr, de Oliveira ALR. Kempe PRG, et al. J Venom Anim Toxins Incl Trop Dis. 2020 May 20;26:e20190093. doi: 10.1590/1678-9199-JVATITD-2019-0093. J Venom Anim Toxins Incl Trop Dis. 2020. PMID: 32518556 Free PMC article. - Fumaric Acids Do Not Directly Influence Gene Expression of Neuroprotective Factors in Highly Purified Rodent Astrocytes.
Pars K, Gingele M, Kronenberg J, Prajeeth CK, Skripuletz T, Pul R, Jacobs R, Gudi V, Stangel M. Pars K, et al. Brain Sci. 2019 Sep 19;9(9):241. doi: 10.3390/brainsci9090241. Brain Sci. 2019. PMID: 31546798 Free PMC article. - BG-12 and its potential for the prevention of relapse in multiple sclerosis.
Giannetti P, Niccolini F, Nicholas R. Giannetti P, et al. Degener Neurol Neuromuscul Dis. 2012 Sep 28;2:119-132. doi: 10.2147/DNND.S35790. eCollection 2012. Degener Neurol Neuromuscul Dis. 2012. PMID: 30890883 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical